Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Stetler-Stevenson Website

William G. Stetler-Stevenson, M.D., Ph.D.

Selected Publications

1)  Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG.
An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.
Oncogene. [Epub ahead of print], 2013.
2)  Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG.
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.
Oncotarget. 4: 163-73, 2013.
3)  Adamson A, Ghoreschi K, Rittler M, Chen Q, Sun HW, Vahedi G, Kanno Y, Stetler-Stevenson WG, O'Shea JJ, Laurence A.
Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and th17 T-helper cell subsets and is a direct stat target gene.
PLoS ONE. 8: e59367, 2013.
4)  Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, Stetler-Stevenson WG, Seo DW.
Antagonism of VEGF-A-induced increase in vascular permeability by an integrin a3ß1-Shp-1-cAMP/PKA pathway.
Blood. 120: 4892-902, 2012.
5)  Stetler-Stevenson W, Bourboulia D, Guedex L, Jensen-Taubman S.
Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development.
Curr. Angiogenesis. 1: 148-56, 2012.
6)  Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.
Cell Cycle. 11: 3649-55, 2012.
7)  Gonçalves AN, Meschiari CA, Stetler-Stevenson WG, Nonato MC, Alves CP, Espreafico EM, Gerlach RF.
Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.
J. Biotechnol. 157: 20-4, 2012.
8)  Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG.
Matrix metalloproteinases: changing roles in tumor progression and metastasis.
Am. J. Pathol. 181: 1895-9, 2012.
9)  Bourboulia D, Jensen-Taubman S, Stetler-Stevenson W.
TIMP-2 An Endogenous Angiogenesis Inhibitor with Distinct Antitumoral Properties.
Treat. Strategies Hematol. 2: 31-35, 2012.
10)  Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG.
TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis.
J. Immunother. 35: 502-12, 2012.
11)  Seo D, Saxinger WC, Guedez L, Cantelmo AR, Albini A, Stetler-Stevenson WG.
An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo.
Peptides. 32: 1840-8, 2011.
12)  Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG.
Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.
Am. J. Pathol. 179: 2589-600, 2011.
13)  Bourboulia D, Stetler-Stevenson WG.
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion.
Semin Cancer Biol. 20: 161-168, 2010.
14)  Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.
Mol. Cell. 37: 333-43, 2010.
15)  Metaferia BB, Rittler M, Gheeya JS, Lee A, Hempel H, Plaza A, Stetler-Stevenson WG, Bewley CA, Khan J.
Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry.
Bioorg. Med. Chem. Lett. 20: 7337-40, 2010.
16)  Guedez L, Stetler-Stevenson WG.
The prognostic value of TIMP-1 in multiple myeloma.
Leuk. Res. 34: 576-7, 2010.
17)  Lee SJ, Tsang PS, Diaz TM, Wei BY, Stetler-Stevenson WG.
TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells.
Lab. Invest. 90: 374-82, 2010.
18)  Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ.
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.
Cancer Sci. 100: 1748-56, 2009.
19)  Sun J, Stetler-Stevenson WG.
Overexpression of tissue inhibitors of metalloproteinase 2 up-regulates NF-kappaB activity in melanoma cells.
J Mol Signal. 4: 4, 2009.
20)  Glassberg MK, Elliot SJ, Fritz J, Catanuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M.
Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness.
J. Clin. Endocrinol. Metab. 93: 1625-33, 2008.
21)  Lee H, Lim C, Lee J, Kim N, Bang S, Lee H, Min B, Park G, Noda M, Stetler-Stevenson WG, Oh J.
TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells.
J. Cell. Biochem. 104: 1065-74, 2008.
22)  Stetler-Stevenson WG.
The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2.
Cancer Metastasis Rev. 27: 57-66, 2008.
23)  Seo D, Kim SH, Eom S, Yoon HJ, Cho Y, Kim P, Kim YK, Han J, Diaz T, Wei B, Stetler-Stevenson WG.
TIMP-2 disrupts FGF-2-induced downstream signaling pathways.
Microvasc. Res. 76: 145-51, 2008.
24)  Kim Y, Seo D, Kong S, Lee J, Lee E, Stetler-Stevenson M, Stetler-Stevenson WG.
TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.
Cancer Lett. 269: 37-45, 2008.
25)  Stetler-Stevenson WG.
Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities.
Sci Signal. 1: re6, 2008.
26)  Haviernik P, Diaz MT, Haviernikova E, Tse W, Stetler-Stevenson WG, Bunting KD.
Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance.
Blood Cells Mol. Dis. 2007.
27)  Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Cancer Res. 67: 7238-46, 2007.
28)  Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T.
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi"s sarcoma.
J. Exp. Med. 203: 1235-47, 2006.
29)  Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG.
Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells.
J. Biol. Chem. 281: 3711-21, 2006.
30)  Chang H, Lee J, Poo H, Noda M, Diaz T, Wei B, Stetler-Stevenson WG, Oh J.
TIMP-2 promotes cell spreading and adhesion via upregulation of Rap1 signaling.
Biochem. Biophys. Res. Commun. 345: 1201-6, 2006.
31)  Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG.
TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118.
Oncogene. 25: 4230-4, 2006.
32)  Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB.
Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta.
J Cell Sci. 118: 2143-53, 2005.
33)  Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K.
CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells.
Blood. 105: 2836-44, 2005.
34)  Larsen MB, Stephens RW, Brünner N, Nielsen HJ, Engelholm LH, Christensen IJ, Stetler-Stevenson WG, Høyer-Hansen G.
Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
Scand J Immunol. 61: 449-60, 2005.
35)  Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, Guedez L, Salloum R, Ginsburg E, Sun Y, Khan N, Hirota M, Wallace-Jones B, Wechselberger C, Vonderhaar BK, Tosato G, Stetler-Stevenson WG, Sanicola M, Salomon DS.
Role of human cripto-1 in tumor angiogenesis.
J. Natl. Cancer Inst. 97: 132-41, 2005.
36)  Stetler-Stevenson WG, Seo DW.
TIMP-2: an endogenous inhibitor of angiogenesis.
Trends Mol Med. 11: 97-103, 2005.
37)  Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Blood. 105: 1660-8, 2005.
38)  Martínez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F.
Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator.
Biochem J. 383: 413-8, 2004.
39)  Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA.
Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.
Stroke. 35: e159-62, 2004.
40)  Feldman AL, Stetler-Stevenson WG, Costouros NG, Knezevic V, Baibakov G, Alexander HR, Lorang D, Hewitt SM, Seo DW, Miller MS, O'Connor S, Libutti SK.
Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism.
Cancer Res. 64: 4481-6, 2004.
41)  Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kern FG, Stetler-Stevenson WG, Lippman ME, Thompson EW.
Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice.
Cancer Res. 64: 652-8, 2004.
42)  Martínez A, Zudaire E, Portal-Núñez S, Guédez L, Libutti SK, Stetler-Stevenson WG, Cuttitta F.
Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth.
Cancer Res. 64: 6489-94, 2004.
43)  Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD.
Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation.
Oncogene. 23: 9212-9, 2004.
44)  Oh J, Seo DW, Diaz T, Wei B, Ward Y, Ray JM, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M, Stetler-Stevenson WG.
Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.
Cancer Res. 64: 9062-9, 2004.
45)  Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Tsilibary EC.
Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells.
Am. J. Physiol. Renal Physiol. 284: F671-9, 2003.
46)  Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG.
Quantitative Assessment of angiogenic responses by the directed in vivo angiogenesis assay.
Amer. J. Pathol. 162: 1431-1429, 2003.
47)  Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG.
TIMP-2 Mediated Inhibition of Angiogenesis: An MMP-Independnet Mechanism.
Cell. 114: 171-180, 2003.
48)  Matsui K, Takano Y, Yu ZX, Hi JE, Stetler-Stevenson WG, Travis WD, Ferrans VJ.
Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy.
Pathol. Res. Pract. 198: 403-12, 2002.
49)  Karamessinis PM, Tzinia AK, Kitsiou PV, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B, Margaritis LH, Tsilibary EC.
Proximal tubular epithelial cell integrins respond to high glucose by altered cell-matrix interactions and differentially regulate matrixin expression.
Lab. Invest. 82: 1081-93, 2002.
50)  Martínez A, Vos M, Guédez L, Kaur G, Chen Z, Garayoa M, Pío R, Moody T, Stetler-Stevenson WG, Kleinman HK, Cuttitta F.
The effects of adrenomedullin overexpression in breast tumor cells.
J. Natl. Cancer Inst. 94: 1226-1237, 2002.
51)  Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ.
Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1 matrix metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma.
Cancer Res. 61: 6322-6327, 2001.
52)  Alper O , Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG.
EGFR-Antisense In Ovarian Carcinoma Cells Reduces Integrin and Metalloproteinase-Mediated Attachment/Migration.
J. Natl. Cancer Inst. 93: 1375-1384, 2001.
53)  Vergani V, Garofalo A, Bani MR, Borsotti P, Parker MP, Drudis T, Mazzarol G, Viale G, Giavazzi R, Stetler-Stevenson WG, Taraboletti G.
Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas.
Int. J. Cancer. 91: 241-7, 2001.
54)  Shankavaram UT, Lai WC, Netzel-Arnett S, Mangan PR, Ardans JA, Caterina N, Stetler-Stevenson WG, Birkedal-Hansen H, Wahl LM.
Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation.
J. Biol. Chem. 276: 19027-32, 2001.
55)  Stetler-Stevenson WG, Yu AE.
Proteases in invasion: matrix metalloproteinases.
Semin. Cancer Biol. 11: 143-52, 2001.
56)  Stetler-Stevenson WG.
The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg. Oncol. Clin. N. Am. 10: 383-92, x, 2001.
57)  Guedez L, Mansoor A, Birkedal-Hansen B, Lim MS, Fukushima P, Venzon D, Stetler-Stevenson WG, Stetler-Stevenson M.
TIMP-1 Regulation of IL-10 in B Cell Differentiation and Lymphomagenesis.
Blood. 97: 1796-1802, 2001.
58)  Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG.
Tissue Inhibitor of Metalloproteinases (TIMP)-1 Alters The Tumorigenicity of Burkitt's Lymphoma Via Divergent Effects on Tumor Growth and Angiogenesis.
Amer. J. Pathol. 158: 1207-1215, 2001.
59)  Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG.
Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Suppresses TKR-Growth Factor Signaling Independent of Metalloproteinase Inhibition. J.
J. Biol. Chem. 276: 3203-3214, 2001.
60)  Hewitt RE, Brown KE, Corcoran M, Stetler-Stevenson WG.
Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line.
J. Pathol. 192: 455-9, 2000.
61)  Galateau-Salle FB, Luna RE, Horiba K, Sheppard MN, Hayashi T, Fleming MV, Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions.
Hum. Pathol. 31: 296-305, 2000.
62)  Lenz O, Elliot SJ, Stetler-Stevenson WG.
Matrix metalloproteinases in renal development and disease.
J. Am. Soc. Nephrol. 11: 574-81, 2000.
63)  Birkedal-Hansen B, Pavelic ZP, Gluckman JL, Stambrook P, Li YQ, Stetler-Stevenson WG.
MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues.
Oral diseases. 6: 376-82, 2000.
64)  Taraboletti G, Sonzogni L, Vergani V, Hosseini G, Ceruti R, Ghilardi C, Bastone A, Toschi E, Borsotti P, Scanziani E, Giavazzi R, Pepper MS, Stetler-Stevenson WG, Bani MR.
Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells.
Exp. Cell Res. 258: 384-94, 2000.
65)  Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG, Tsoskas M.
Validation of a model of colon cancer progression.
J. Pathol. 192: 446-54, 2000.
66)  Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, Chung V, Corcoran ML, Kleiner DE, Stetler-Stevenson WG.
Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions.
J. Biol. Chem. 274: 21362-8, 1999.
67)  Giannelli G, Pozzi A, Stetler-Stevenson WG, Gardner HA, Quaranta V.
Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids.
Am. J. Pathol. 154: 1193-201, 1999.
68)  Marchetti C, Cornaglia I, Casasco A, Bernasconi G, Baciliero U, Stetler-Stevenson WG.
Immunolocalization of gelatinase-A (matrix metalloproteinase-2) in damaged human temporomandibular joint discs.
Arch. Oral Biol. 44: 297-304, 1999.
69)  Kleiner DE, Stetler-Stevenson WG.
Matrix metalloproteinases and metastasis.
Cancer Chemother. Pharmacol. 43 Suppl: S42-51, 1999.
70)  Stetler-Stevenson WG.
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.
J. Clin. Invest. 103: 1237-41, 1999.
71)  O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA.
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance.
J. Biol. Chem. 274: 29568-71, 1999.
72)  Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Mol. Cell. Biol. 19: 5902-12, 1999.
73)  Lim MS, Guedez L, Stetler-Stevenson WG, Stetler-Stevenson M.
Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes.
Ann. N. Y. Acad. Sci. 878: 522-3, 1999.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/1/2013.